Overview of ALN-KHK Preclinical Development Program Presented at American Diabetes Association 83rd Scientific Sessions

Overview of ALN-KHK Preclinical Development Program Presented at American Diabetes Association 83rd Scientific Sessions

We presented an overview of the preclinical development program for ALN-KHK, an investigational RNAi therapeutic for type 2 diabetes mellitus, at the American Diabetes Association (ADA) 83rd Scientific Sessions.

Noetzli, et al. “Preclinical Development of ALN-KHK, an Investigational RNAi Therapeutic for Type 2 Diabetes Mellitus”